Samantha McGill, NP
Family · Ocean Springs, MSNPI 1962741223
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,291 of the $12,702 with a category attached, or 88.9%. It is spread thinly across 46 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 639 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- Novo Nordisk$2K
- Dexcom, Inc.$973
- Lilly USA, LLC$956
- Bayer$771
- plus $4K from 40 others
What the payments were for
- Travel & lodging$1,26010%
- Food & beverage$11,29189%
- Education$1511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INPEN SMART INSULIN DELIVERY SYSTEM$726
- InPen$547
- Korlym$121
- FARXIGA$109
- FreeStyle Libre$108
How this compares
$12,702 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 344 | $406,189 |
| MounjaroTirzepatide | 252 | $321,940 |
| JardianceEmpagliflozin | 252 | $242,417 |
| Tresiba Flextouch U-200Insulin Degludec | 136 | $119,702 |
| TrulicityDulaglutide | 86 | $109,866 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 70 | $88,250 |
| FarxigaDapagliflozin Propanediol | 72 | $64,653 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $45,865 |
| KerendiaFinerenone | 30 | $33,178 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $32,127 |
| TymlosAbaloparatide | 11 | $29,337 |
| Novolog FlexpenInsulin Aspart | 98 | $28,157 |
| NovologInsulin Aspart | 98 | $26,832 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $25,946 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $23,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $1,622 | $452,974460 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $956 | $438,870381 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $272 | $268,944285 claims |
| AstraZenecaFarxiga | $410 | $64,65372 claims |
| BayerKerendia | $771 | $33,17830 claims |
| Radius Health, Inc.Tymlos | $106 | $29,33711 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $255 | $23,31818 claims |
| AmgenProlia | $390 | $22,51713 claims |
| MerckJanuvia | $120 | $22,49522 claims |
| Johnson & JohnsonInvokana | $23 | $13,63020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $7,189155 claims |
| AbbVieSynthroid | $233 | $4,92057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Ocean Springs
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.